Literature DB >> 14610340

Nephropathy in a hypercholesterolemic mouse model with streptozotocin-induced diabetes.

Samar M Hammad1, Debra J Hazen-Martin, Mimi Sohn, Leslie Eldridge, Lyn Powell-Braxton, Wesley Won, Timothy J Lyons.   

Abstract

BACKGROUND/AIMS: The contribution of preexisting hypercholesterolemia to diabetic nephropathy remains unclear. We assessed the impact of hypercholesterolemia on diabetic nephropathy using a double knockout (DKO) mouse, null for the low-density lipoprotein receptor (LDLRNDASH;/NDASH;) and the apoB mRNA editing catalytic polypeptide 1 (APOBEC1NDASH;/NDASH;).
METHODS: Wild-type (WT) and DKO mice received sham or streptozotocin injections at age 7 weeks, yielding control (WT-C, DKO-C) and diabetic (WT-D, DKO-D) groups. At sacrifice (age 40 weeks), albuminuria was determined by ELISA, and kidney sections were examined by light and electron microscopy.
RESULTS: Albuminuria increased in diabetic mice (WT-D: 82.4 +/- 37.2 microg/18 h; DKO-D: 58.0 +/- 45.7 microg/18 h) versusnondiabetic controls (WT-C: 10.2 +/- 7.2 microg/18 h; DKO-C: 8.6 +/- 5.3 microg/18 h) (p LT; 0.0001), but was unaffected by hypercholesterolemia. Light microscopy of kidney sections demonstrated increased collagen levels in glomeruli in WT-D mice, but not in DKO-D mice or either control group. Electron microscopy showed a thickened glomerular basement membrane in WT-D mice only. The proximal tubular basement membrane thickness was increased in both diabetic groups versusnondiabetic controls (p LT; 0.01); in WT-D mice this was attributable to collagen accumulation, but in DKO-D mice it was mainly caused by lipid vacuoles.
CONCLUSIONS: In this animal model, preexisting hypercholesterolemia did not exacerbate either glomerular lesions of diabetes (collagen accumulation, basement membrane thickening) or albuminuria, but appeared to mitigate these effects. Furthermore, the combination of hypercholesterolemia and diabetes resulted in a significant lipid accumulation in the tubular basement membrane. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610340     DOI: 10.1159/000073942

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  4 in total

1.  High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats.

Authors:  R Babaei-Jadidi; N Karachalias; C Kupich; N Ahmed; P J Thornalley
Journal:  Diabetologia       Date:  2004-12-11       Impact factor: 10.122

2.  A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy.

Authors:  Xianghong Zhu; Andrew M Herzenberg; Mohammad Eskandarian; Graham F Maguire; James W Scholey; Philip W Connelly; Dominic S Ng
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 3.  Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches.

Authors:  Suvi E Heinonen; Guillem Genové; Eva Bengtsson; Thomas Hübschle; Lina Åkesson; Katrin Hiss; Agnes Benardeau; Seppo Ylä-Herttuala; Ann-Cathrine Jönsson-Rylander; Maria F Gomez
Journal:  J Diabetes Res       Date:  2015-02-15       Impact factor: 4.011

4.  Novel Nongenetic Murine Model of Hyperglycemia and Hyperlipidemia-Associated Aggravated Atherosclerosis.

Authors:  Susanne Gaul; Khurrum Shahzad; Rebekka Medert; Ihsan Gadi; Christina Mäder; Dagmar Schumacher; Angela Wirth; Saira Ambreen; Sameen Fatima; Jes-Niels Boeckel; Hamzah Khawaja; Jan Haas; Maik Brune; Peter P Nawroth; Berend Isermann; Ulrich Laufs; Marc Freichel
Journal:  Front Cardiovasc Med       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.